PR92430

HUDSON, Wis., Oct. 19, 2021 /PRNewswire=KYODO JBN/ --

- Medical and pharmaceutical solutions leader poised to scale manufacturing

from new and expanded production facilities and R&D centers in Poland, China

and U.S.

- End-to-end capabilities optimize design, development and manufacturing of

world-class healthcare products and solutions while reducing time, cost and risk

- Industry-leading collaborations with Eyevensys, GlucoModicum and Credence

MedSystems accelerate delivery of technology breakthroughs and next-gen products

Phillips-Medisize (https://c212.net/c/link/?t=0&l=en&o=3327347-1&h=1542476432&u=https%3A%2F%2Fwww.phillipsmedisize.com%2F%3Futm_source%3Dpress-outreach%26utm_medium%3Dprrelease%26utm_content%3DPhillips-Medisize%2520Expansion%2520%26utm_campaign%3D7018W000000inIsQAI&a=Phillips-Medisize),

a Molex company and leader in the design and manufacture of drug delivery,

diagnostic and MedTech devices, announces the expansion of its global

manufacturing footprint, along with extended product design, development and

manufacturing capabilities to streamline the delivery of game-changing products

and solutions. The company's global reach now encompasses 36 world-class

facilities with scalable, end-to-end capabilities tailored to help customers

bring groundbreaking products to market quickly and efficiently from anywhere

in the world.

Photo -

https://mma.prnewswire.com/media/1663581/Growing_footprint_of_Phillips_Medisize.jpg

"As the preferred partner for leading global customers, we continually invest

in new talent and technologies that increase the capacity and capabilities of

Phillips-Medisize across the entire value chain," said Paul Chaffin, president,

Medical and Pharmaceutical Solutions, Molex. "Our expanded global reach and

resources will enable us to solve complex development and manufacturing

challenges while meeting escalating customer demands for more localized

production, supply chain management and accelerated go-to-market strategies."

Growing Footprint for Local Support, Global Scale

To address growing production demands from customers in continental Europe,

Phillips-Medisize is building a state-of-the-art medical manufacturing facility

in Katowice, Poland. Slated to open in 2022, the site will complement

production sites and innovation centers in Asia, Europe, India, Mexico and

North America. Phillips-Medisize also is expanding production capacity in

Suzhou, China to serve both global and regional pharmaceutical and MedTech

customers. Additionally, the transformation of an existing Molex production

facility in Little Rock, Ark., is underway, enabling Phillips-Medisize to keep

pace with ever-increasing requirements in the U.S. for high-volume, diagnostic

device manufacturing.

Once these expansions are complete, Phillips-Medisize will offer nearly three

million square feet/280,000 square meters of country- and region-specific

manufacturing space and R&D capabilities worldwide. The company also will

support 600,000 square feet/55,000 square meters of Class 7 and 8 cleanrooms,

which complement existing tool building sites as well as global quality and

regulatory systems. In 2020, Phillips-Medisize completed a new facility in St.

Croix Meadows, Wisc., with 285,000 square feet/26,000 square meters supporting

production of molded components for medical diagnostic customers requiring

high-volume assembly and packaging of regulated products. The facility also

includes a nearly 64,000 square-foot/6,000 square-meter ISO 14644-1 Class 8

cleanroom.

Extending End-to-End Capabilities

As part of its one-stop shop of medical-device manufacturing solutions,

Phillips-Medisize focuses on design for manufacturability and assembly

excellence. Proven front-end innovation, human-factors engineering, and quality

are integrated with regulatory adherence to reduce go-to-market risk and cost.

Expanded capabilities in complex molding, drug and reagent handling, as well as

final packaging and serialization, enable customers to consolidate global

supply chains while optimizing go-to-market strategies.

Phillips-Medisize's combined expertise in plastics, metals, electronics and

connectivity ease the development of different solutions, including combination

devices such as needle-based injection systems and wearable injection

technologies. An unwavering commitment to rigorous quality management is

reinforced by dedicated New Product Introduction (NPI) teams at every site.

Strategic investments in talent acquisition to support Phillips-Medisize's

continued growth are expected to add at least 1,000 employees worldwide over

the next couple of years.

Optimizing Industry-Leading Collaborations

A strong track record of collaboration ensures Phillips-Medisize is at the

forefront of the latest advancements in drug delivery, diagnostic and MedTech

devices. Today, Credence MedSystems announced (https://c212.net/c/link/?t=0&l=en&o=3327347-1&h=122506672&u=https%3A%2F%2Fwww.credencemed.com%2Fabout%2Fnews%2F%23tab3&a=Credence+MedSystems+announced) a strategic initiative with Phillips-Medisize (https://c212.net/c/link/?t=0&l=en&o=3327347-1&h=673569949&u=https%3A%2F%2Fexperience.molex.com%2Ffortifying-healthcare-innovation-from-the-frontlines%2F%3Futm_source%3Dpress-outreach%26utm_medium%3Dprrelease%26utm_content%3DBlog%2Bfrom%2BPhillpis%2BExpansion%2BPress%2BRelease%2B%26utm_campaign%3D7018W000000inIsQAI&a=strategic+initiative+with+Phillips-Medisize) that includes ramping production of the Credence Companion(R) and Dual

Chamber Reconstitution Systems at the Phillips-Medisize Letterkenny, Ireland

site and the new facility in Poland.

"We're excited to leverage Phillips-Medisize's world-class manufacturing as we

scale toward high-volume automation at the new state-of-the-art facility in

Poland," said Jeff Tillack, COO at Credence MedSystems. "The opportunity to

scale production in close proximity to our operations and European customers

will accelerate market delivery of our innovative solutions to meet the needs

of our pharma customers and their end-users."

In September, GlucoModicum entered into a design and development program

(https://c212.net/c/link/?t=0&l=en&o=3327347-1&h=3101633794&u=https%3A%2F%2Fglucomodicum.com%2Fglucomodicum-and-phillips-medisize-sign-a-design-and-development-program-for-the-rapid-scale-up-of-its-needle-free-continuous-glucose-monitor%2F&a=GlucoModicum+entered+into+a+design+and+development+program)

with Phillips-Medisize for the rapid scale-up of manufacturing for its

Talisman needle-free continuous glucose monitor, which uses unique

magnetohydrodynamic (MHD) technology. Also last month, Paris-based Eyevensys

announced an engagement (https://c212.net/c/link/?t=0&l=en&o=3327347-1&h=3673616776&u=https%3A%2F%2Fwww.eyevensys.com%2Feyevensys-enters-collaboration-with-phillips-medisize-and-minnetronix-medical%2F&a=Eyevensys+announced+an+engagement) with Phillips-Medisize to optimize the design, development and high-volume

manufacturing of its ocular device component that powers the delivery of novel

gene therapies for treating various eye diseases.

Phillips-Medisize Brings Possibilities to Life

Phillips-Medisize, a Molex company, brings decades of innovation to leading

healthcare and life science companies to develop groundbreaking solutions that

help people live healthier, more productive lives. On average, the company

commercializes 50 new products a year for customers, including the

first-to-market FDA-registered drug-delivery device utilizing a connected

health system. Molex brings decades of experience in advanced electronics,

connectivity and sensor technologies to help transform medical and

pharmaceutical solutions.

About Molex

Molex is a global electronics leader committed to making the world a better,

more-connected place. With presence in more than 40 countries, Molex enables

transformative technology innovation in the automotive, data center, industrial

automation, healthcare, 5G, cloud and consumer device industries. Through

trusted customer and industry relationships, unrivaled engineering expertise,

and product quality and reliability, Molex realizes the infinite potential of

Creating Connections for Life. For more information, visit www.molex.com.

SOURCE  Molex

CONTACT: Sue Hetzel, HetzelMeade Communications, on behalf of Molex,

sue@hetzelmeade.com, 760.473.4729